ArticleAnnals of clinical and translational neurology2016
Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy.
Article in Annals of clinical and translational neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Nicotinamide Mononucleotide Adenylyltransferase 1 and NADMetabolites · 2026Review
- Mitochondrial NMNAT3 reduces amyloid aggregates inMitochondrial communications · 2026Article
- CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New-Onset Refractory Status Epilepticus.Annals of clinical and translational neurology · 2025Article
- Article
- Nmnat1 Modulates Mitochondrial Oxidative Stress by Inhibiting Caspase-3 Signaling in Alzheimer's Disease.Journal of molecular neuroscience : MN · 2021Article
- Exposure to Mild Steel Welding and Changes in Serum Proteins With Putative Neurological Function-A Longitudinal Study.Frontiers in public health · 2020Article
- Circadian clock protein Rev-erbα regulates neuroinflammation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Metabolic aspects of neuronal degeneration: From a NADNeuroscience research · 2019Review
- Deep Profiling of the Aggregated Proteome in Alzheimer's Disease: From Pathology to Disease Mechanisms.Proteomes · 2018Review
- NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy.Behavioural brain research · 2018Article
- Quantifying the cellular NAD+ metabolome using a tandem liquid chromatography mass spectrometry approach.Metabolomics : Official journal of the Metabolomic Society · 2017Article
- NMNAT3 is protective against the effects of neonatal cerebral hypoxia-ischemia.Annals of clinical and translational neurology · 2017Article
- NMNAT: It's an NADCurrent opinion in genetics & development · 2017Review
- Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.Science translational medicine · 2017Article
- Meat Intake and the Dose of Vitamin BInternational journal of tryptophan research : IJTR · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveThe nicotinamide-nucleotide adenylyltransferase protein Nmnat1 is a potent inhibitor of axonal degeneration in models of acute axonal injury. Hyperphosphorylation and aggregation of the microtubule-associated protein Tau are associated with neurodegeneration in Alzheimer's Disease and other disorders. Previous studies have demonstrated that other Nmnat isoforms can act both as axonoprotective agents and have protein chaperone function, exerting protective effects in drosophila and mouse models of tauopathy. Nmnat1 targeted to the cytoplasm (cytNmnat1) is neuroprotective in a mouse model of neonatal hypoxia-ischemia, but the effect of cytNmnat1 on tauopathy remains unknown.
methodsWe examined the impact of overexpression of cytNmnat1 on tau pathology, neurodegeneration, and brain functional connectivity in the P301S mouse model of chronic tauopathy.
resultsOverexpression of cytNmnat1 preserved cortical neuron functional connectivity in P301S mice in vivo. However, whereas Nmnat1 overexpression decreased the accumulation of detergent-insoluble tau aggregates in the cerebral cortex, it exerted no effect on immunohistochemical evidence of pathologic tau phosphorylation and misfolding, hippocampal atrophy, or inflammatory markers in P301S mice.
interpretationOur results demonstrate that cytNmnat1 partially preserves neuronal function and decreases biochemically insoluble tau in a mouse model of chronic tauopathy without preventing tau phosphorylation, formation of soluble aggregates, or tau-induced inflammation and atrophy. Nmnat1 might thus represent a therapeutic target for tauopathies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.